J&J Remicade

Executive Summary

Remicade (infliximab) growth will continue in face of Abbott's roll out of Humira, Johnson & Johnson says. "We expect to see continued solid growth through the balance of this year, and we expect to be able to compete very effectively with both Humira and Enbrel," J&J Company Group Chairman in Charge of Biologics Franchise Joseph Scodari says. "Remicade is likely the most potent drug in this category, and that is by far and away the focal point of our clinical positioning," Scodari adds. U.S. Remicade sales were $345 mil. for the first quarter, a 46% increase...